文献速递细菌感染、耐药与抗菌药物医院感染防控

中国禁用黏菌素促生长添加剂后动物与人类大肠杆菌黏菌素耐药及mcr-1丰度变化:流行病学比较研究

Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study.
PubMed 文献 · Lancet Infect Dis · 2020-06-04

该流行病学比较研究评估中国2017年4月30日禁用黏菌素促生长添加剂后,2015至2019年动物和人类大肠杆菌中黏菌素耐药及mcr-1丰度的变化。结果显示农业黏菌素产量和销售额大幅下降,猪和鸡粪便中黏菌素耐药大肠杆菌(CREC)和mcr-1丰度显著降低,健康人群mcr-1阳性大肠杆菌(MCRPEC)携带率及临床CREC感染比例也显著下降。结论认为禁用政策显著减少了动物和人类黏菌素耐药,但需持续监测。

要点

  • 禁用黏菌素促生长添加剂后,猪和鸡粪便CREC分离率及mcr-1丰度显著下降。

核心结论

  • 中国禁用黏菌素促生长添加剂及农业使用减少显著降低了动物和人类黏菌素耐药。
  • 持续黏菌素监测对医院黏菌素管理预警至关重要。

研究设计与样本

  • 流行病学比较研究,分析中国兽药协会2015-2018年农业黏菌素产销数据。
  • 基于动物源耐药监测数据库分析23省市猪和鸡2015-2016及2017-2018年CREC流行率。
  • 检测4省118家农场(60猪、29鸡、29牛)2017和2018年粪便黏菌素残留及mcr-1。
  • 比较24省市健康体检者2016年与2019年MCRPEC携带率。
  • 基于中国细菌耐药监测网分析26省市医院2015-2016及2018-2019年临床CREC感染比例。

临床怎么用

  • 临床应认识到禁用黏菌素促生长添加剂后人类黏菌素耐药下降,但仍需警惕CREC感染。
  • 建议医院持续监测黏菌素耐药,作为黏菌素管理预警系统。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following the discovery and emergence of the plasmid-mediated colistin resistance gene, mcr-1, the Chinese government formally banned colistin as an animal growth promoter on April 30, 2017. Herein, we report patterns in colistin resistance and mcr-1 abundance in Escherichia coli from animals and humans between 2015 and 2019, to evaluate the effects of the colistin withdrawal. METHODS: We did an epidemiology comparative study to investigate: annual production and sales of colistin in agriculture across mainland China according to data from the China Veterinary Drug Association from 2015 to 2018; the prevalence of colistin-resistant E coli (CREC) in pigs and chickens in 23 Chinese provinces and municipalities as reported in the China Surveillance on Antimicrobial Resistance of Animal Origin database from Jan 1, 2015, to Dec 31, 2016, and Jan 1, 2017, to Dec 31, 2018; the presence of residual colistin and mcr-1 in faeces from 118 animal farms (60 pig, 29 chicken, and 29 cattle) across four provinces over July 1, 2017, to August 31, 2017, and July 1, 2018 to August 31, 2018; the prevalence of mcr-1-positive E coli (MCRPEC) carriage in healthy individuals attending routine hospital examinations across 24 provinces and municipalities from June 1 to July 30, 2019, comparing with equivalent 2016 data (June 1 to September 30) from our previous study in the same hospitals; and the patterns in CREC prevalence among hospital E coli infections across 26 provinces and municipalities from Jan 1, 2015, to Dec 31, 2016, and Jan 1, 2018, to Dec 31, 2019, reported on the China Antimicrobial Surveillance Network. FINDINGS: After the ban on colistin as a growth promoter, marked reductions were observed in the production (27 170 tonnes in 2015 vs 2497 tonnes in 2018) and sale (US$71·5 million in 2015 vs US$8·0 million in 2018) of colistin sulfate premix. Across 118 farms in four provinces, mean colistin residue concentration was 191·1 μg/kg (SD 934·1) in 2017 versus 7·5 μg/kg (50·0) in 2018 (p<0·0001), and the median relative abundance of mcr-1 per 16S RNA was 0·0009 [IQR 0·0001-0·0059] in 2017 versus 0·0002 [0·0000-0·0020] in 2018 (p=0·0001). Across 23 provinces and municipalities, CREC was identified in pig faeces in 1153 (34·0%) of 3396 samples in 2015-16 versus 142 (5·1%) of 2781 in 2017-18 (p<0·0001); and in chickens in 474 (18·1%) of 2614 samples in 2015-16 versus 143 (5·0%) of 2887 in 2017-18 (p<0·0001). In hospitals across 24 provincial capital cities and municipalities, human carriage of MCRPEC was identified in 644 (14·3%) of 4498 samples in 2016 versus 357 (6·3%) of 5657 in 2019 (p<0·0001). Clinical CREC infections in 26 provinces and municipalities comprised 1059 (1·7%) of 62 737 E coli infections in 2015-16 versus 794 (1·3%) of 59 385 in 2018-19 (p<0·0001). INTERPRETATION: The colistin withdrawal policy and the decreasing use of colistin in agriculture have had a significant effect on reducing colistin resistance in both animals and humans in China. However, continuous colistin monitoring is essential, in particular to act as an early warning system for colistin stewardship in Chinese hospitals. FUNDING: National Key Research and Development Program of China, National Natural Science Foundation of China, and UK Medical Research Council.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wang Y, Xu C, Zhang R, et al. Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study. Lancet Infect Dis. 2020. PMID: 32505232. doi:10.1016/S1473-3099(20)30149-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。